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Chapter 1 
1. Introduction 
1.1. Cigarette smoke and cigarette smoke-related diseases 
1.1.1. Cigarette smoke composition 
Cigarette smoke (CS), is the dominant cause of preventable deaths that endangers the 
longevity and life quality of humans (Chen et al., 2020). It is well known that more 
than 5000 detrimental chemical compounds and at least 55 carcinogens are involved 
in the CS (National Center for Chronic Disease et al., 2012, Chen et al., 2020). CS is 
an aerosol of liquid droplets generated by the combustion of tobacco during the 
smoking, containing about 1010 particles/mL (Valavanidis A et al., 2009). In general, 
CS consists of mainstream smoke (MSS) and sidestream smoke (SSS) (Fig. 1.1) 
(Thielen et al., 2008). The former is directly inhaled by the smoker, and the latter is 
absorbed from the surroundings of the burning cigarette. Two phases are involved in 
the MSS, namely a tar (particle) phase and a remaining gas phase. The gas phase (0.4 
− 0.5 g/cigarette) is mainly comprised of air constituents, oxygen and nitrogen. The 
extent of particles in fresh MSS ranges between 0.1 and 1 μm in diameter, and the 
weight is around 4.5% of the whole smoke (Thielen et al., 2008). A great number of 
mutagenic and carcinogenic agents, such as PAHs, N-nitrosamines, and phytosterols, 
are mostly found in the particulate phase only (Valavanidis A et al., 2009). The 
compounds of SSS both in the gas and particle phase are similar to those of MSS. The 
gas phase can infiltrate and transit the lung alveolus and damage tissues remote from 
the lung, suggesting it is more vital for human health (Yamaguchi et al., 2007). 
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Figure 1.1 The sidestream smoke and mainstream smoke of a burning cigarette. 
(Reproduced with permission from (Thielen et al., 2008). 
 
1.1.2. Cigarette smoke-related diseases 
It is well established that CS could affect negatively most human body systems (Fig 
1.2), such as respiratory, cardiovascular and musculoskeletal diseases. The most 
common CS-related diseases are cardiovascular disease (CVD) (McEvoy et al., 2015), 
chronic obstructive pulmonary disease (COPD) (Laniado-Laborin, 2009), and diverse 
types of cancer, in particular lung cancer (Warren and Cummings, 2013). Cigarette 
smoking can damage the airway and pass through the lung alveolus, resulting in lung 
diseases and injury to other tissues. Smokers have a higher possibility (12 - 13 times) 
of dying from COPD than non-smokers, and CS is a major risk that triggers an attack 
in patients with asthma (National Center for Chronic Disease et al., 2014). Moreover, 
smokers have as much as a 30-fold increased risk of developing lung cancer or dying 
from lung cancer compared with non-smokers (National Center for Chronic Disease 
et al., 2014). Besides, exposure to cigarette smoke predisposes the individual to 
several diseases that affect heart and blood vessels (Barua et al., 2015). CS has been 
reported to cause approximately 140,000 premature deaths annually from CVD 
(National Center for Chronic Disease et al., 2014). 
Furthermore, exposure to the environment of smoked tobaccos among non-smokers 
also increases the health risk of respiratory (Oberg et al., 2011) and cardiovascular 
(Raghuveer et al., 2016) problems，as well as lung cancer (Manning et al., 2017). 
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However, owing to the loose regulation of tobacco products and difficulty in quitting 
smoking, the global tobacco control efforts are disappointing. 
 
Figure 1.2 The effects of smoking on the human body. Smoking can damage every 
part of the body. 
 
1.1.3. Cigarette smoke and musculoskeletal disorders 
Although the detrimental effects of smoking for human health have been well 
accepted, less attention has been paid by researchers to the relevance of CS to 
musculoskeletal disease. The musculoskeletal system, which provides support and 
motion to the body, is made up of skeletal bones, connective tissues (ligaments, 
tendons, and cartilage), as well as skeletal muscles (Al-Bashaireh et al., 2018). 
Several preclinical and clinical researches have examined the association between CS 
and the musculoskeletal system, its impact on the prognosis of several orthopaedic 
disorders, surgical complications and prolonged hospital stays (Ehnert et al., 2019, 
Greenberg et al., 2017, Sloan et al., 2010, Chen et al., 2020). Our lab has previously 
assessed and compared the fracture healing capacities of smokers and non-smokers 
among 1585 patients. The outcome of the study showed that smoking significantly 
increased surgical complications and delayed healing, which resulted in prolonged 
hospital stays in smokers when compared to non-smokers (Fig 1.3). Recent evidence 
has demonstrated that smoking could cause an imbalance between bone 
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mineralization and absorption, resulting in lower bone mass and bone mineral density 
(BMD) (Ward and Klesges, 2001) and predisposing bone to osteoporosis and fracture 
(Law and Hackshaw, 1997). 
 
Figure 1.3 Effect of smoking on the hospital stay and surgical complication 
during fracture healing. Data from 1585 patients of the BG Unfallklinik Tübingen 
shows smokers encounter significantly more complications and longer hospital stays 
than non-smokers (*p < 0.05) (Reproduced with permission from (Ehnert et al., 
2019). 
 
1.1.4. Cigarette smoke and osteoarthritis 
The relationship between CS and osteoarthritis (OA) has been assessed by several 
epidemiological surveys, but the results are controversial. CS has been thought to 
have a defensive effect against OA, through reducing body weight (Chiolero et al., 
2008) and stimulating anabolic action of chondrocyte by nicotine (Ying et al., 2012). 
In one follow-up study, Felson et al. (Felson et al., 1997) found that smokers had a 
lower incidence (28%) of OA than that of non-smokers (37.5%), after adjustment for 
multiple risk factors (age, sex, and weight). Similarly, in a retrospective study, Cerhan 
et al. found consistent results with those of the aforementioned study (Cerhan et al., 
1996). However, the protective effect of smoking is minimal, and the methods of 
evaluation and selection bias may be inaccurate, leading to the results of these studies 
not being conclusive. 
Recently, more and more researches have shown a positive relationship between CS 
and cartilage loss with the assistance of Magnetic Resonance Imaging (MRI) (Chen et 
al., 2020). Davies-Tuck and his colleagues indicated that smokers were related to 
increased medial knee cartilage loss, and a positive relationship between pack-year 
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(PY) smoked and the loss of cartilage bulk was observed (Davies-Tuck et al., 2009). 
Furthermore, in a cross-sectional analysis, Ding et al. suggested that smoking leads to 
an increase in knee cartilage loss and defects in subjects with a family history of knee 
OA (Ding et al., 2007). Nevertheless, these studies are only based on radiographic 
images (MRI, X-ray) or post-operative outcomes (Ding et al., 2007, Dube et al., 
2016), and no direct research yet has evaluated the effects of CS on human cartilage 
or primary human chondrocytes. Thus, these results may be not conclusive, since the 
structural changes of cartilages within the smoker’s joints are still not known (Chen et 
al., 2020). 
 
1.2. Osteoarthritis and cartilage 
1.2.1. Osteoarthritis epidemiology 
OA is a type of chronic disabling disease that affects millions of people all over the 
world (El-Tawil et al., 2016) (Fig. 1.4). It is a common form of arthritis and affects 
both large and small joints in the body, including hips, knees, hands, and feet (Allen 
and Golightly, 2015). Over the past decades, along with the increasing rate of joint 
injuries and obesity, the prevalence and burden of OA have consistently risen (March 
et al., 2014). In the recent Global Burden of Disease (GBD) 2015 Study, OA and 
diabetes accounted for the largest increases in burden disability of years lived with 
disability (YLDs) worldwide, when comparing the data of 1990−2005 with 
2005−2015 (Collaborators, 2016). OA accounted for 3.9% of YLDs in 2015 in the 
global population, and it is predicted to climb to the fourth leading cause of YLDs by 
2020, while it ranked sixth in 2003 (Silverwood et al., 2015). Overall, the incidence 
of OA is higher in women compared with men, as well as increasing with age. 
Approximately 15% of females and 9% of males aged over 60 have symptomatic 
knee OA (Hunter and Bierma-Zeinstra, 2019). 
In the clinic, the most susceptible site of OA is the knee, followed by the hand and the 
hip (Prieto-Alhambra et al., 2014). The knee and hip, two pivot joints in humans, are 
more prone to cause disability and comorbidity compared with other joints. 
Throughout the world, the prevalence of OA has been estimated to be 0.85% and 3.8% 
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for hip OA and knee OA, respectively (March et al., 2014). Approximately 85% of the 
burden of OA is occupied by knee OA, causing billions in medical costs every year 
(Collaborators, 2016). 
 
Figure 1.4 OA epidemiology and demographics. Age-standardized 
disability-adjusted life year rates for osteoarthritis by country (per 100,000 
inhabitants). (Reproduced with permission from (El-Tawil et al., 2016). 
 
1.2.2. Cartilage structure and morphology 
Human articular cartilage (AC) is a smooth, viscoelastic tissue, which coats and 
protects the ends of long bones. This specially designed structure possesses the 
function of decreasing friction and distributing loading, owing to its high content of 
components, including the incompressible water as well as the cartilaginous matrix 
(proteoglycans, collagen fibrils, etc.) (Archer, 2003). In healthy cartilage, water is 
estimated to account for 65% to 80% of the mass in the deep and surface layer, 
respectively (Sophia Fox et al., 2009, Akkiraju and Nohe, 2015). Water content 
increases with OA, leading to increased permeability, decreased strength as well as a 
decreased Young’s modulus of elasticity (Otero et al., 2012). Approximately 10% - 20% 
of cartilage gross mass is made of collagen, and 90% - 95% of the collagen is 
occupied by collagen II (Akkiraju and Nohe, 2015). Some small amounts of collagens 
(type V, VI, IX, X, and XI) and additional macromolecules are also present. The 
function of collagen is to provide a cartilaginous framework and tensile strength 
(Akkiraju and Nohe, 2015). Proteoglycans comprise 10 to 15% of cartilage and 
possess the functions of water condense and compressive strength support (Sophia 
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Fox et al., 2009). Large proteoglycan, also refers to aggrecan, attached through a link 
protein and is mostly responsible for hydrophilic behavior (Sophia Fox et al., 2009). 
In general, AC is structured in four laminar zones: superficial, transitional, deep and 
calcified zones (Davies and Kuiper, 2019) (Fig 1.5). Chondrocytes are derived from 
mesenchymal stem cells (MSCs) and exclusively found in the AC (Akkiraju and Nohe, 
2015). They possess the properties of proliferating and synthesizing extracellular 
matrix (ECM) to support the functionality and stability of AC (Archer, 2003, Chen et 
al., 2020). Owing to the high volume of matrix, only 1%–5% of the total cartilage is 
occupied by chondrocytes (Akkiraju and Nohe, 2015). Chondrocytes are entrapped in 
lacuna and separated by ECM, leading to their not being able to migrate to the lesion 
sites (Archer, 2003). Since cartilage is a tissue without a blood supply, chondrocytes 
are nourished through diffusion from synovium and subchondral bone (Hugle and 
Geurts, 2017). Moreover, these cells live in an environment with low oxygen content, 
resulting in their low metabolic turnover. Chondrocytes are metabolically active cells 
and respond to outside stimuli such as cytokines and mechanical changes. These 
factors are of great necessity to the degradation and regeneration of ECM (Scanzello 
and Goldring, 2012).  
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Figure 1.5 The structure of AC and underlying subchondral bone. There are four 
zones from the cartilage surface to the bone: the superficial, middle, deep and 
calcified zones. (Reproduced with permission, from (Davies and Kuiper, 2019). 
 
1.2.3. Pathophysiology of OA 
OA is a whole-joint disease, involving cartilage breakdown, osteophytes formation, 
synovial inflammation, degeneration of ligaments and menisci, as well as weakness of 
periarticular muscles (Hunter and Bierma-Zeinstra, 2019, Chen et al., 2020). The 
degeneration of cartilage is highly correlated with systemic risk factors (gender, aging, 
genetic heritability, nutrition, and smoking) and local risk factors (obesity, joint 
mechanics, occupational stress, physical activity, and injury) (Silverwood et al., 2015). 
In the traditional concept, OA was thought to be a condition of cartilage deterioration 
owing to increased mechanical loading. It was speculated that persistent mechanical 
loading disrupted ECM, which overruns the regeneration of cartilage by itself (Chen 
et al., 2017). Therefore, OA was defined simply as the damaged cartilage due to wear 
9 
 
and tear. Nevertheless, the onset and mechanism of OA are still unclear according to 
this explanation. Recently, this concept is being challenged, as the pathogenesis of OA 
is not so simple. The current view is that OA is a condition with a multifaceted 
etiology, including biomechanical factors (Guilak, 2011), cytokines (Fernandes et al., 
2002), and proteases (Troeberg and Nagase, 2012), and this change is more nuanced. 
During the process of OA, the earliest change that occurs in cartilage is the shift of 
chondrocytes from a normally quiescent condition to activated cells as a 
compensatory mechanism, characterized by cell proliferation, cluster formation and 
increased synthesis of matrix molecules (collagen, aggrecan, and hyaluronan) 
(Goldring and Goldring, 2007). Nevertheless, in the end, the death of chondrocytes 
along with the alteration in the ECM prevail and change the development of OA. The 
initial degenerative switch in the AC brings about cartilage weakening and increased 
production of fragmented particles, which stimulate the release of pro-inflammatory 
cytokines, like TNFα, IL-1, and IL-6 (Scanzello and Goldring, 2012). Once secreted, 
these cytokines are able to affix to the receptors of chondrocytes or synoviocytes, 
contributing to the release of metalloproteinases such as matrix metalloproteinases 
(MMPs) and aggrecanases, which in turn accelerates cartilage degradation and 
fragmentation (Hwang and Kim, 2015). Increased cartilage fragments further induce 
the release of pro-inflammatory cytokines and proteases, forming a vicious cycle. 
Changes in the subchondral bone include the increase in bone turnover, development 
of bone marrow lesions, and vascular invasion from the subchondral bone through the 
tidemark into the cartilage (Hunter and Bierma-Zeinstra, 2019). In later stages, 
significant aseptic bone necrosis takes place and synovial fluid diffuses into the bone 
marrow, leading to bone cysts (Man and Mologhianu, 2014). 
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Figure 1.6 Signaling pathways and structural changes in the development of OA. 
(Reproduced with permission from (Hunter and Bierma-Zeinstra, 2019). 
 
1.2.4. Symptoms of OA 
Symptoms of OA often appear slowly and worsen over time. Pain is the hallmark of 
OA and a major driver of seeking clinical advice (Hunter et al., 2008). Swelling, 
morning stiffness, limited range of motion (ROM), muscle weakness, joint instability 
and crepitus are also observed frequently in OA patients (Hunter and Bierma-Zeinstra, 
2019). Radiographic evidence of the disease includes synovial thickening, joint space 
narrowing, and the formation of osteophytes (Braun and Gold, 2012). Sadly, neither 
complete cure nor satisfactory diagnostics are currently available to reverse the 
condition. 
 
1.2. Current treatments of OA 
Nowadays, treatment designed for OA is variable (Fig 1.7). In general, conservative 
treatment strategies of OA include non-pharmacological as well as pharmacological 
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treatments. They are employed for patients with early or less advanced stages 
(Kellgren and Lawrence, K-L Grade 1–3) of OA for relieving pain, increasing joint 
mobility, and improving life quality (Ringdahl E, 2011). In the end stage (K-L Grade 
4) of OA, surgery is the definitive option (Ronn et al., 2011). 
 
Figure 1.7 Ladder of treatment for knee OA. Treatment strategy varies from the 
mild (bottom), moderate to the advanced (top). 
 
1.3.1. Non-pharmacological treatment 
To date, all guidelines recommend that non-pharmacological treatments should play a 
core role in managing OA patients (Zhang et al., 2008, Silverwood et al., 2015, 
Nelson et al., 2014). Non-pharmacological methods such as patient education, regular 
exercise, weight control, physiotherapy, and assistive devices are recommended and 
treated as first-line treatment (Zhang et al., 2008). Most guidelines strongly 
recommend education and self-management as part of the administration of OA, 
including information about the pathophysiology of the disease, joint protection 
strategies, different treatment approaches and also about surgery when it is necessary 
(Zhang et al., 2008, Block, 2014). Performing moderate exercise is helpful in 
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improving joint flexibility, reducing pain and strengthening muscle in the leg and 
knee. Patients should be advised to participate in endurance or strengthening exercises 
and low-impact aerobic exercise (running, swimming, etc.), and lose weight if they 
are overweight or obese (Jordan et al., 2003). For obese persons, losing weight and 
augmenting physical health may help to alleviate the stress on the knees, and reduce 
symptoms. Several trials have clearly demonstrated a positive association between 
weight loss and symptom amelioration (Allen and Golightly, 2015). The use of braces 
and assistive devices are often recommended but not well defined, as they may be 
effective for reducing physical stress on the knees and relieving symptoms (Nelson et 
al., 2014). Other alternatives and complementary therapies, like acupuncture, taichi, 
transcutaneous electrical nerve stimulation and therapeutic ultrasound are still 
controversial in different guidelines, as there is insufficient evidence to support their 
efficacy (Block, 2014, Jordan et al., 2003).  
 
1.3.2. Pharmacological treatment 
Pharmacological treatments mostly often recommended in the guidelines are 
acetaminophen (Ace), non-steroidal anti-inflammatory drugs (NSAIDs), opioid 
analgesics, and intra-articular (IA) injections (Ringdahl E, 2011). As pain is the main 
symptom of and influence on the life quality of OA patients, analgesics are widely 
performed as a vital remedy for moderate-to-severe OA in clinic. Ace (Hunter and 
Bierma-Zeinstra, 2019) and NSAIDs (Dougados, 2006) are essential medicine and 
recommended as the first-line pain medication for OA by most guidelines. Although 
the efficacy of Ace has been well documented, the dosage should be limited since 
overdosing with Ace may be toxic to the liver (McGill and Jaeschke, 2014). 
Compared with Ace, NSAIDs have a stronger anti-inflammatory effect. Some studies 
have administered randomized controlled trials (RCTs) and meta-analysis to compare 
the safety and efficacy of Ace and NSAIDs, suggesting NSAIDs are more effective 
than Ace regarding pain relief (Towheed et al., 2006, Pavelka, 2004). However, side 
effects regarding gastrointestinal and cardiovascular complications should be 
considered in selecting these drugs. The dose and frequency of oral analgesic agents 
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are preferably restricted at the minimum effective level (Sostres et al., 2010). 
Additionally, as adjunctives or alternatives, topical NSAIDs can be as effective as oral 
analgesic agents in treating knee OA (R. and RL, 2009). There was no evidence that 
topical NSAIDs could cause serious gastrointestinal or renal adverse events in the 
general population. Some local reaction such as itching, skin irritation and burning are 
observed more frequently (Hunter and Bierma-Zeinstra, 2019). Recently, it was well 
established that IA injection of Ace (Arun et al., 2013) and NSAIDs (Thing et al., 
2014) were effective in suppressing inflammation and alleviating pain in joints, 
indicating that it would be a promising alternative to delay joint demolishment for 
patients with OA. When patients with refractory pain or Ace and NSAIDs are 
ineffective or contraindicated, more potent drugs are necessary, such as opioids. 
Opioids, both oral and transdermal administration, have potent effects on pain 
alleviation and function promotion of patients with hip or knee OA (Ringdahl E, 
2011). Benefits obtained from the use of opiates, however, can be outweighed by the 
frequent adverse effects, such as nausea, dizziness, vomiting, constipation and 
sleepiness (Fuggle et al., 2019). In addition, dependence or addiction to opiates is 
another potential risk, therefore low effective and tolerated doses are recommended 
(Lipman, 2001). 
Nowadays, IA injections of corticosteroids (CSs) and hyaluronic acid (HA) have been 
widely and successfully applied in treating knee OA(Wernecke et al., 2015, Concoff 
et al., 2017). IA injections of CSs, such as dexamethasone (Dex), hydrocortisone, and 
methylprednisolone, have been frequently used in alleviating joint symptoms and 
inhibiting inflammation, and their efficacy has been evaluated in many clinical trials 
(Grodzinsky et al., 2017, Stove et al., 2002). Osteoarthritis Research International 
(OARIS) recommended that IA injections of CSs should be performed after patients 
failing to respond, or having an unsatisfactory response, to oral analgesic/anti- 
inflammatory agents (Zhang et al., 2008). HA is the main component of cartilage 
ECM and synovial fluid in both healthy and OA joints (Akmal M, 2005, 
Temple-Wong et al., 2016, Chen et al., 2020). Most of the guidelines recommend that 
IA injection of HA (Wernecke et al., 2015, Baron et al., 2018) as a 
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viscosupplementation for OA joints, owing to HA concentration is decreased in the 
synovial liquid of pathologic joints compared with healthy joints (Akmal M, 2005, 
Temple-Wong et al., 2016, Chen et al., 2020).  The characteristics of IA injection of 
HA are delayed onset and prolonged duration of symptomatic benefits in comparison 
with CSs injections (Trueba Davalillo et al., 2015). 
Other drugs, such as chondroitin, glucosamine, antidepressants, sex hormones, herbal 
remedies, and vitamins are recommended by some guidelines, but little detail was 
given and there no consensus achieved (Nelson et al., 2014). 
 
1.3.3. Surgical treatments  
1.3.3.1. Arthroscopic lavage and debridement  
Arthroscopic surgeries including lavage and debridement have been extensively 
applied in the management of OA. In theory, arthroscopic lavage could relieve joint 
pain secondary to OA by way of clearing up the debris as well as inflammatory 
cytokines that may lead to synovitis and pain (Ronn et al., 2011). Nevertheless, there 
is no evidence to support the benefit of arthroscopic lavage. In a systematic review, 
Reichenbach et al. evaluated data from 567 patients in seven randomized trials, and 
found that joint lavage was no more effective in pain relief or function improvement 
than control groups (a sham intervention, a placebo injection, and a nonintervention 
control) (Reichenbach et al., 2010). 
Arthroscopic debridement should be used to treat patients with torn meniscal 
fragments, and isolated OA without meniscal tear should be avoided. Dervin et al. 
showed that patients with evident meniscus lesions or cartilage flaps might benefit 
from this surgery (Dervin et al., 2003). This result was similar to another study, in 
which middle-aged patients were selected, and arthroscopic debridement was found to 
be beneficial to transient relief of symptoms (Hubbard, 1996). In a systematic review, 
after two years, insignificant difference was observed in pain relief in the arthroscopic 
intervention groups compared with control treatments (sham surgery, exercise, or 
medical treatment) (Thorlund et al., 2015). 
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1.3.3.2. Cartilage repair techniques 
1.3.3.2.1 Microfracture surgery 
Microfracture surgery is a technique that works by drilling a hole to penetrate the 
underlying bone. Theoretically, this technique causes MSCs derived from the 
subchondral bone marrow to differentiate into chondrocytes, promoting 
chondrogenesis in the defective area (Ronn et al., 2011). This is a relatively quick and 
simple operation and can be done through arthroscopy. The peculiarity of 
mini-incision and ease of handling of this technique results in its broad use (Erggelet 
and Vavken, 2016). On the other hand, forming fibrocartilage rather than hyaline 
cartilage and possible functional deterioration are the drawbacks one should be aware 
of (Mithoefer et al., 2009). 
 
1.3.3.2.2 Osteochondral graft transplantation  
Osteochondral graft transplantation is one of the most established techniques for 
reconstruction of a cartilaginous surface. Osteochondral grafts are made up of 
cartilage and bone from other parts of the body (osteochondral autograft) or from a 
tissue donor (osteochondral allograft), and replace both the AC and the subchondral 
bone (Ronn et al., 2011). This allows the defective area to be refilled immediately 
with mature and intact hyaline cartilage by using an arthroscopic or mini-invasive 
procedure (Richter et al., 2016b). The superiority of this technique is the lesion of 
cartilage can be substituted with a similar tissue. Minor integration, possible disease 
transmission, restricted donor sites, and complexity of handling are the disadvantages 
of this procedure (Ronn et al., 2011). According to the recent literature, a lesion with 
dimensions < 2 cm2 is the best indication that can be treated through microfracture 
(first-line option) or osteochondral graft transplantation (Richter et al., 2016a). 
Compared with microfracture, osteochondral graft transplantation showed results of 
more longevity and durability, especially among patients with high functional demand 
(Karmali et al., 2019). 
 
1.3.3.2.3 Autologous Chondrocyte Implantation (ACI) 
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ACI technique includes two-stage surgical procedures with laboratory processing, 
which was first reported clinically by Brittberg et al in 1994 (Brittberg et al., 1994). 
In this technique, cartilage is sampled from non-weight-loading regions and then 
digested enzymatically to isolate chondrocytes, subsequently, these cells are cultured 
in vitro for several weeks and reimplanted on the damaged area of cartilage (Brittberg, 
2008). Although chondrocyte repairs the defect with tissue resembling hyaline 
cartilage, some issues remain, including low proliferation in their nature, 
dedifferentiation during in vitro expansion and limited cells being available (Schnabel 
et al., 2002). Additionally, donor-site morbidity caused by cartilage harvest, multiple 
surgical procedures, high cost and the lack of definitive scientific evidence to justify 
its large-scale use all limit the usage of ACI (Brittberg, 2008). 
 
Figure 1.8 Schematic illustration of ACI. The procedure consists of two steps: (1) 
cartilage harvested from non-weight-loading regions and cultured in in vitro 
environment; and (2) reimplantation of the cells by injecting them into the lesion. 
(Reproduced with permission from (Bauge and Boumediene, 2015). 
 
1.3.3.3. Osteotomy 
It has been widely noted that joint malalignment plays a fundamental role in OA onset 
and progression. Osteotomy is performed to relieve pain (particularly in patients with 
symptoms) and delay the onset or progression of OA through realigning the joints 
(Ronn et al., 2011). Different surgical techniques are used to adjust the load axis, 
including high tibial osteotomy (HTO) and distal femoral osteotomy (DFO) (Fig 1.9). 
HTO is commonly performed in patients with varus deformity, either by wedging 
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open bone from the proximal tibia to reconfigure the knee joint (Lee and Byun, 2012). 
Similarly, DFO is usually performed in patients with valgus deformity by closing the 
medial wedge of bone or wedging open lateral femur (Feucht et al., 2017). 
Osteotomies around the knee are effective, particularly in young patients or 
middle-aged active patients with predominantly unicompartmental OA. However, 
postoperative complications such as fracture, nonunion, nerve injury, as well as the 
risk of additional surgery following osteotomy should be taken into account (Sherman 
et al., 2018). Thus, appropriate patient selection, correct osteotomy types, and proper 
surgical techniques are essential to guarantee the success of osteotomy. 
 
Figure 1.9 Postoperative X-ray images of HTO and DFO. (a) Open-wedge HTO in 
unicompartmental OA of the medial knee compartment (Lee and Byun, 2012) and (b) 
open-wedge DFO in unicompartmental OA of the lateral knee compartment. 
(Reproduced with permission from (Feucht et al., 2017). 
 
1.3.3.4. Joint arthroplasty 
It is well accepted that joint arthroplasty is a safe and highly effective procedure for 
patients with severe OA (Grayson and Decker, 2012). In the light of its irreversible 
nature, this surgery is only recommended for patients who have failed to respond, or 
having an unsatisfactory response, to other treatments (Ronn et al., 2011). Owing to 
the limited endurance of prosthetic components, which is normally 15 to 20 years, 
arthroplasties are normally performed in patients older than 60 years old (Hunter and 
Bierma-Zeinstra, 2019). In general, knee joint arthroplasties contain 
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unicompartmental knee arthroplasty (UKA) and total knee arthroplasty (TKA) (Fig 
1.10). The former is indicated in cases of OA with merely one side of damaged 
cartilage, and the latter is executed in patients with more than one lesion compartment 
involved or after the failure of other surgeries (Ahmad et al., 2015). Moreover, UKA 
is usually performed in patients with well-preserved lateral compartments, including 
intact meniscus, cartilage and cruciate ligaments (Arirachakaran et al., 2015). TKA is 
recommended in patients with more than one lesion compartment involved, and 
considerable improvements in the function and life quality have been shown (Aujla 
and Esler, 2017). The long-term follow-up study of TKA indicated that the survival 
rate was 92.7% and 90.4% at 10 years and 15 years, respectively (Feng et al., 2013). 
The main reasons for failure were aseptic loosening of components and infections 
(Feng et al., 2013). 
 
Figure 1.10 Plain radiographs of the TKA and UKA. (a) Anteroposterior (AP) 
view after the TKA surgery. (b) Lateral view after the TKA surgery. (c) AP view after 
the UKA surgery. (d) Lateral view after the UKA surgery(Reproduced with 
permission from (Ronn et al., 2011). 
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1.4. Aim of the study 
The objective of this thesis was to perform comparative analysis of 2-D monolayer 
and 3-D culture of primary human chondrocytes to establish an optimal cell culture 
model. The following points shall be addressed: 
1. To evaluate the effects of cigarette smoke extract (CSE) with different 
concentrations on the viability, function, and gene expression of primary 
human chondrocytes.  
2. “To research the possible mechanism by which CSE affects primary human 
chondrocytes.” (Chen et al., 2020) 
3. To evaluate whether the pharmacologic treatment of dexamethasone is 
beneficial to chondrocytes impaired by CSE, and if not, whether it could be 
substituted by other treatments, such as acetaminophen or NSAIDs. 
4. To evaluate the effects of HA and HA combinations (dexamethasone, 
acetaminophen or diclofenac) on chondrocytes impaired by CSE. 
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Chapter 2 
2. Materials and Methods 
2.1. Materials  
2.1.1. Chemicals and reagents 
Table 2.1: List of used chemicals and reagents. 
 
Substance  Article No. Company  
Acetic Acid Glacial (100%)  20104.298 VWR 
1,9-Dimethyl-Methylene Blue Zinc Chloride 
Double Salt (DMMB) 341088 Sigma 
2′, 7′-Dichlorfluorescein-Diacetate (DCFH-DA) 21884 Sigma  
4-Nitrophenyl Phosphate Disodium Salt 
Hexahydrate (pNPP) 4165.1 Carl Roth 
4-Nitrophenyl Sodium 10 mM N7660 Sigma 
Acetaminophen A5000 Sigma  
Agarose 2267.4 Roth 
Alcian Blue 3082.2 Carl Roth 
Ammonium Thiocyanate 221988-100g Sigma 
Antibiotic/Antimycotic Stock Solution P11-002 PAA 
Boric Acid 99.8% p.a 6943.1 Carl Roth 
Bromophenol A512.1 Carl Roth 
Calcein Acetoxymethyl Easter (Calcein AM) ABD-22002 ATT Bioquest 
Chloroform Y015.1 Carl Roth 
Chondroitin Sulfate A Sodium Salt from bovine 
trachea C9819 Sigma  
Collagenase II 17454.01 Serva 
Deoxyribonucleic Acid from Calf Thymus D4522 Sigma  
Dulbecco’s Modified Eagle Medium (DMEM) D6546 Sigma 
Dexamethason Water Soluble D2915 Sigma  
Diclofenac Sodium Salt D6899 Sigma  
Diethylpyrocarbonate (DEPC) K028.3 Carl Roth 
Dimethyl Sulfoxide (DMSO) 4720.2 Carl Roth 
Disodium Hydrogen Phosphate 7876.7 Carl Roth 
Dulbecco's Phosphate Buffered Saline (DPBS) D8537 Sigma 
Ethanol 99.9% p.a. (EtOH) 20821.33 VWR 
Ethidium Bromide 1% 2218.1 Carl Roth 
Fetal Calf Serum (FCS) 41G7141K Invitrogen 
First Strand cDNA Synthesis Kit K1621 ThermoFisher 
Formaldehyde, 37% solution A0823.1000 AppliChem 
Glycerol, >99% p.a. G6376-100G Sigma 
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2.1.2. Buffers, medium and solutions 
Table 2.2: List of buffers, medium and solutions. 
 
Glycine  3908.2 Carl Roth 
Glycine, >99%, p.a. A1067.5000 AppliChem 
Guanidine Hydrochloride G3272 Sigma  
Guanidine Thiocyanate 0017.1 Carl Roth 
Hoechst 33342 14533-100MG Sigma 
Hyaluronic Acid Sodium 53747 Sigma  
Hydrogen Chloride (HCl) 4625.2 Roth 
Isopropanol 100% 20842.33 VWR 
Isopropanol 100% 33539 Honeywell 
L-Ascorbate-2-Phosphate A8960-5G Sigma 
Magnesium Chloride KK36.2 Carl Roth 
Methanol >99% (Met OH) 20847.307 VWR 
N-Acetyl-L-Cyteine 4126.2 Carl Roth 
Papain from papaya latex P4762 Sigma  
Paraformaldehyde 335.2 Carl Roth 
Penicillin/Streptomycin (P/S) P0781 Sigma 
Resazurin Sodium Salt 199303-1G Sigma 
Roti Aqua Phenol A980.3 Carl Roth 
Safranin-O T129.1 Carl Roth 
Sodium Acetate X891.2 Carl Roth 
Sodium Chloride S7653-1KG Sigma 
Sodium Chloride S7653 Sigma  
Sodium Ethylene Diamine Tetraacetatic Acid 
(Na-EDTA) 8043.2 Roth 
Sodium Hydroxide (NaOH) T135.1 Carl Roth 
Sulforhodamine B Sodium Salt S1402-1G Sigma 
Trisamine (Tris) Base, >99%, p.a. T1503-1KG Sigma 
Trisaminomethan AE15.1 Roth 
TrizolQIAzol Lysis Reagent 79306 Qiagen 
Trypan Blue CN76.1 Roth 
Trypsin/EDTA T3924 Sigma  
 
Buffers/Mediums/Solutions Compounds and handling 
Calcein AM stock solution 502 µl DMSO 
1 mg Calcein AM 
Trypan blue solution 62.5 mg Trypan blue 
50 ml Dulbecco’s PBS 
Alcian blue solution (1%, PH 2.5) 500 mg Alcian blue (8 GX) 
50 ml Acetic Acid (3%) 
Guanidine Hydrochloride (6 M) 28.65 mg Guanidine Hydrochloride 
50 ml ddH2O 
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Safranin-O solution (0.1%) 50 mg Safranin-O 
50 ml ddH2O 
Formaldehyde (4%) Formaldehyde (37%) in ddH2O 
AP Activity Assay buffer (PH 10.5) 2 g 4-nitrophenyl-phosphate (0.2%) 
3.75 g Glycine (50 mM) 
12.11 g Tris-Base (100 mM) 
95.21 mg MgCl2 (1 mM) 
1 L ddH2O 
PCR loading buffer 25 mg Bromophenol blue 
5 ml 10X TBE 
5 ml Glycerol (20%) 
10 X TBE buffer 108 g TRIS 
55 g Boric acid 
40 ml EDTA (0.5 M, PH 8) 
1 L ddH2O 
Ethanol solution (70%) 99% Ethanol in ddH2O 
Sodium Acetate solution (3M, PH 5) 12.3 g Sodium Acetate in 50 ml ddH2O 
Acetic Acid Solution (1%) 100% acetic acid in ddH2O 
Acetic Acid Solution (3%) 100% acetic acid in ddH2O 
TRIS Solution (10 mM) 1.2g TRIS in 1L ddH2O 
SRB Solution 0.4% SRB in 1% acetic acid 
Resazurin stock solution 0.025% in DPBS 
Resazurin working solution 10% Resazurin stock solution in DPBS 
PBE Buffer (PH 6.5) 6.5 mg N-Acetyl-L-Cyteine 
138 mg Disodium hydrogen phosphate 
14.9 mg EDTA 
Adjust PH to 6.5 with NaOH 
Adjust volume to 20 ml with ddH2O 
Papain stock solution (5 mg/ml) 5 mg papain from papaya latex 
1 ml PBE buffer 
Papain working solution (25 µg/ml) 5 mg/ml stock solution in PBE buffer 
DMMB solution buffer (PH 3) 304 mg Glycine 
160 mg sodium chloride 
9.5 ml 0.1 M Acetic acid 
90.5 ml ddH2O 
DMMB stock solution (8 mg/ml) 8 mg DMMB in 1 ml buffer 
DMMB working solution (16 µg/ml) 8 mg/ml stock solution in DMMB buffer 
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2.1.3. Consumables 
Table 2.3: List of consumables 
 
 
Chondroitin Sulfate Standards stock 
solution 
(1 mg/ml) 
10 mg Chondroitin Sulfate Standards in 
10 mlPBE buffer 
Chondroitin Sulfate Standards working 
solution 
(100 µg/ml) 
1 mg/ml stock solution in PBE buffer 
TE buffer (PH 7.5-8.0) 10 mM Tris base 
1 mM EDTA 
Calf Thymus DNA stock solution (1 
mg/ml) 
1 mg Calf Thymus DNA in 1 ml TE 
buffer 
TNE buffer (PH 7.4) 121.1 mg Tris Base 
37.2 mg EDTA 
1.17 g sodium chloride 
Adjust PH to 7.4 with HCl 
Adjust volume to 100 ml with ddH2O 
Chondrocyte Cells Culture Medium 500 ml DMEM  
+500 ml Ham's F12  
+50 ml FCS  
+10 ml Penicillin/Streptomycin  
+50 µl L-Ascorbic-2-Phosphate 
 
Consumable  Manufacturer Type Serial number 
Cell culture plate Greiner bio-one 
96-well,flat 
bottom 655180 
Cell culture plate Greiner bio-one 
96-well, V  
bottom 651101 
Cell culture plate CorningInc. 
48-well,flat 
bottom 3548 
Cell culture plate Greiner bio-one 
24-well,flat 
bottom 662160 
Cell culture plate Corning Inc. 
6-well, flat  
bottom 353046 
Cell Star Tubes Greiner bio-one 50 ml 227261 
Cell Star Tubes Greiner bio-one 15 ml 188271 
Eppendorf tube SARSTEDT AG 0.5 ml, white 72.699 
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2.1.4. Equipment 
2.1.4. Equipment 
Table 2.4: List of used equipment. 
 
Eppendorf tube Carl Roth GmbH + Co.KG 1.5 ml, white 4182.1 
Eppendorf tube Carl Roth GmbH + Co.KG 1.5 ml, blue   4190.1 
Eppendorf tube Carl Roth GmbH + Co.KG 1.5 ml, green 4209.1 
Eppendorf tube Carl Roth GmbH + Co.KG 1.5 ml, red 4189.1 
Eppendorf tube Carl Roth GmbH + Co.KG 1.5 ml, yellow  4204.1 
Eppendorf tube Eppendorf 2.0 ml, white 2549 
Pipette Tips Sorenson BioScience, Inc.  0.1 - 10 μl Colorless 
Pipette Tips Sarstedt AG & Co. 2 - 200 μl Yellow 
Pipette Tips Ratiolab GmbH 100 - 1000 μl Blue 
Single-channel Pipette Corning Inc. 10-100 μl 158240031 
Single-channel Pipette Corning Inc. 20-200 μl 158250088 
Single-channel Pipette Corning Inc. 100-1000 μl 058261237 
Single-channel Pipette Eppendorf  0.1-2.5 μl P35434B 
Spectrophotometer BMG Labtech GmbH Fluostar Omega 415-1264 
Water-bath Lauder Dr. R. Wobser GmbH Al 25 
LCB 
0727-11-0094 
Water-bath Lauder Dr. R. Wobser GmbH ECO ET 20 LY 06.1 
 
Equipment Manufacturer Type Serial number 
Agitator, 
magnetic stirrer IKA-Werke GmbH  RH B2 06.050357 
Agitator, 
magnetic stirrer Heidolph Instruments GmbH MR Hei-Mix L 040700340 
Centrifuge Dako Deutschland GmbH Stat Spin 620E50000693 
Centrifuge Thermo Fisher Scientific Megafuge 40 R 41307652 
Centrifuge Scientific Industries Inc. SI DD 58 DD58-1001 
Centrifuge (Mirco) Labnet International BN 08060235 C1301B 
Centrifuge (Mirco) HERAEUS Med GmbH Fresco 17 41250019 
Electrophoresispower 
supplies Bio-Rad Laboratories GmbH Power Pac 200 285BR05538 
Freezer -20℃ BSH IQ500 
GS51NYW41 
(01) 
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Freezer -20℃ Liebherr Med Line 
LGex3410-21K 
001 
Freezer -80 ℃ Thermo Fisher Scientific 905 827860-2521 
Freezer -86 ℃ Revco ULT1386-9-V17 R10G-333095-RG 
Fridge +4 ℃ Liebherr Comfort 3523-21L 
Fridge +4 ℃ Cool Compact Kühlgeräte G HKMT 040-01 CC00412514 
Gas washing bottle 
Lenz Laborglass GmbH & 
Co.KG 100 ml 5500537 
Gas washing bottle 
Lenz Laborglass GmbH & 
Co.KG 250 ml 5500549 
Ice maker Scotsmen AF 80 DD 8837 11 X 
Incubator  Thermo Fisher Scientific 
Heratherm 
OMS 60 41296334 
Incubator Binder GmbH 9040-0078 11-22649 
Incubator Binder GmbH 9040-0081 11-22190 
Laboratory 
pump (Bench) Carl Roth GmbH + Co.KG Cyclo 2 1109-065 
Microscope PeqlabBiotechnologie GmbH EVOS-fl 91-AF-4301 
Mixer Corning Inc. Vortex Mixer 804995 
Mixer Labinco BV LD-76 76000 
Multichannel Pipette Corning Inc. 5-50 μl 151620022 
Multichannel Pipette Corning Inc. 20-200 μl 551630277 
Multichannel Pipette Thermo Electron Co. 0.5-10 μl CH98998 4510 
Multichannel Pipette Corning Inc. 50-300 μl 151640033 
PCR thermal cyclers Thermo Fisher Scientific Arktik 10040953 
PCR thermal cyclers Applied Biosystems GmbH Forschungslabor 50132 
pH meter Mettler-Toledo GmbH Five Easy FE 20 1232315296 
Pipette controller Integra GmbH Pipetboyacu 629619 
Pipette controller Heathrow Scientific LLC Rota-Filler 3000 HSA05119 
Refrigerator  Cool Compact Kühlgeräte G HKMT 040-01 CC 00412516 
Refrigerator  Cool Compact Kühlgeräte G HKMN 062-01 CC 00412513 
Safety workbench Thermo Fisher Scientific 
Maxisave 
S20201.8 41293949 
Safety workbench Thermo Fisher Scientific 
Maxisave 
S20201.8 41293948 
Scale Kern &Sohn GmbH ABJ 120-4M WB 1140084 
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2.2 Ethics Statement 
All human studies were performed in accordance with the latest revision of the 
Helsinki declaration. All human tissues were obtained in accordance with the ethical 
vote (653/2018BO2) of Eberhard-Karls University and the patients’ written consent. 
The average age of donors for primary chondrocytes isolation was 69.64 ± 8.82 years 
(10 males and 4 females). 
 
2.3 Methods  
2.3.1. Generation of Cigarette Smoke Extract (CSE) 
We used two commercial cigarettes (Marlboro, Philip Morris, New York City, USA) 
to prepare fresh CSE. In brief, the cigarettes were constantly combusted into a 
standard gas washing bottle with a 50 ml pre-warmed DMEM medium. Here two 
cigarettes were bubbled at a speed of 95 bubbles/min. The concentration of CSE was 
measured by a plate reader at λ = 320 nm (OD320). An OD320 of 0.7 was regarded as 
100% CSE. The fresh CSE was passed through a 0.22 μm pore filter to ensure sterility, 
and then it was diluted further (0.1, 0.5, 1, 5, 10, 20, 50%) with chondrocyte culture 
Shaker, laboratory LTF Labortechnik GmbH DRS 12 11DE243 
Shaker, laboratory PeqlabBiotechnologie GmbH ES-20 010111-1107-0119 
Shaker, laboratory LTF Labortechnik GmbH DRS 12 11DE090 
Shaker, Laboratory  Corning Inc. LSE Vortex Mixer 1101260 
Single-channel Pipette Corning Inc. 0.5-10 μl 158220060 
Single-channel Pipette Corning Inc. 2-20 μl 158230441 
Single-channel Pipette Corning Inc. 10-100 μl 158240031 
Single-channel Pipette Corning Inc. 20-200 μl 158250088 
Single-channel Pipette Corning Inc. 100-1000 μl 058261237 
Single-channel Pipette Eppendorf  0.1-2.5 μl P35434B 
Spectrophotometer BMG Labtech GmbH Fluostar Omega 415-1264 
Water-bath Lauder Dr. R. Wobser GmbH Al 25 
LCB 
0727-11-0094 
Water-bath Lauder Dr. R. Wobser GmbH ECO ET 20 LY 06.1 
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medium. The CSE concentrations correspond to exposure associated with smoking 
from 0.01 pack (0.1%) to 1 pack (10%) cigarettes/day (Sreekumar et al., 2017, Chen 
et al., 2020). 
 
2.3.2. Isolation and culture of primary human chondrocytes 
We obtained samples of primary human chondrocytes from osteoarthritic patients 
undergoing total knee arthroplasty. Isolation and culture of primary human 
chondrocytes were mentioned as previously described (Tendulkar et al., 2019). In 
short, the cartilages were chopped into pieces and washed with DPBS (w/o Ca2+/Mg2+) 
thoroughly. Subsequently, these pieces were subjected to collagenase (1500 U/mL) 
digestion in a 37 ℃ shaker incubator overnight, then the supernatant of the mixture 
was obtained by centrifugation to eliminate impurities. Finally, these cells were 
expanded in culture medium at 37 °C and 5% CO2. The cell culture medium with or 
w/o CSE was changed every 24 hours until 3, 7 and 14 days post-inoculation (Chen et 
al., 2020). 
 
2.3.3. Chondrocyte pellet culture 
Chondrocyte pellets were formed in polypropylene 96-well conical plates with 
2.5 × 105 cells per pellet (Solchaga et al., 2011). In brief, after centrifugation at 600 g 
for 10 min, pellets were resuspended at a density of 1.25 × 106 cells/ml in the 
chondrocyte culture medium. Subsequently, 200 µl aliquots of the cell suspension (2.5 
× 105 cells/well) were dispensed into 96-well conical plates and spun in a benchtop 
centrifuge at 600 g for 10 min. Afterward, the pellets were cultured at 37 °C under a 
gas mixture of 95% air/5% CO2. Medium change was performed twice a week. 
 
2.3.4. Resazurin Conversion Assay  
To measure cell viability (mitochondrial activity) of primary human chondrocytes, a 
resazurin conversion assay was performed. In short, after half an hour incubation with  
0.0025% (w/v) Resazurin working solution (in PBS) in a 37°C incubator, the 
fluorescence  (ex/em = 540/590 nm) was evaluated by a plate reader, as the protocol 
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described before (Ehnert et al., 2018, Chen et al., 2020). 
 
2.3.5. Sulforhodamine B (SRB) Staining to assess total protein content 
To assess the total protein content of primary human chondrocytes, SRB staining was 
performed as reported before (Ehnert et al., 2018, Chen et al., 2020). In short, cells 
were fixed with ice-cold ethanol for 30 min at -4°C, and then stained with SRB 
working solution (0.4% w/v in 1% v/v acetic acid) at RT for 30 min followed by 3 
washing steps with acetic acid (1% v/v) to eliminate unbound SRB. After dissolving 
the bound SRB in unbuffered TRIS solution (10 mM, pH ~10.5), the absorbance was 
recorded at λ = 565 nm with a plate reader. 
 
2.3.6. Determination of sulfated glycosaminoglycan (sGAG) content 
The content of sGAG was determined to assess the matrix formation of chondrocytes. 
Briefly, the pellets were transferred into 1.5-ml micro-centrifuge tubes (one pellet per 
tube) and washed with PBS. One ml papa in working solution was added into each 
tube, then the mixtures were incubated at 60℃ overnight. DMMB dye (1,9 - 
Dimethyl - Methylene Blue zinc chloride double salt) was performed to quantify the 
sGAG content with chondroitin sulfate A (0–50 mg/mL) as a standard. The amount of 
sGAG was quantified by measuring the color shift (blue to purple) at λ = 530 nm and 
λ = 590 nm, respectively, in a plate reader (Babur et al., 2013). 
 
2.3.7. DNA Quantification 
DNA content was determined by Calf thymus DNA (ct-DNA) assay, as the 
manufacturer’s protocol decribed before. In brief, 100 µl of standard or sample was 
mixed with 100 µl of Hoechst 33342 dye working solution in a fluorescence plate and 
analyzed (ex/em = 355/460 nm) in a plate reader (Solchaga et al., 2011). 
 
2.3.8. Live/dead staining  
Calcein AM (living cell staining ) and Ethidium homodimer (dead cell staining ) were 
considered as indirect parameters of cell viability. Following the washing with PBS 3 
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times, chondrocytes exposed to the culture medium with or w/o CSE were stained 
with a mixture of 2 µM Calcein AM, 4 µM Ethidium homodimer and 1 mg/ml 
Hoechst 33342 at RT for 30 min. The stained cells were visualized under a 
fluorescence microscope (Mi et al., 2016, Chen et al., 2020). 
 
2.3.9. Assessing ECM production by Alcian blue and Safranin-O staining 
In order to evaluate the generation of glycosaminoglycans (GAGs) and collagen, 
Alcian blue and Safranin-O staining were performed (Tendulkar et al., 2019). In short, 
cells were fixed with 4% V/V formaldehyde for 30 min at RT followed by a washing 
step in PBS. Subsequently, cells were labeled with 1% w/v Alcian blue and 0.1% w/v 
Safranin-O staining at RT for 30 min, respectively. Afterwards, distilled water was 
added to eliminate the unbounded dye solution. All images were photographed with 
an EVOSfl microscope. After dissolving the bound Alcian blue staining with 6 M 
guanidine HCl in distilled water, the optical density was recorded at λ = 620 nm using 
a plate reader  (De Bari et al., 2001, Chen et al., 2020). 
 
2.3.10. Determination of Reactive oxygen species (ROS) production  
ROS production was measured using 2′,7′-dichlorofluorescein-diacetate (DCFH-DA). 
In short, 10 μM DCFH-DA dissolved in serum-free culture medium was 
supplemented to cells after washing with PBS and incubated for at 37 °C for 30 min. 
Then cells were exposed to CSE after washing with PBS. The measurement of 
fluorescence intensity was obtained by a plate reader (ex/em = 485/520 nm) following 
15 min of incubation (Sreekumar et al., 2017, Chen et al., 2020). 
 
2.3.11. Alkaline Phosphatase (AP) Activity Assay 
AP activity is considered as a hypertrophic marker of chondrocytes (Nadzir et al., 
2011). In short, AP reaction buffer was added to cells after washing with PBS and 
incubated in a 37°C incubator for one hour. Then, absorbance was determined using a 
plate reader (λ = 405 nm / OD405) as described (Sreekumar et al., 2017). The 
normalization was performed by Resazurin conversion (Chen et al., 2020). 
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2.3.12. Semi-Quantitative RT-PCR 
The TriFAST reagent was used to collect total RNA based on the manufacturer’s 
instructions (Tendulkar et al., 2019). Complementary DNA (cDNA) was synthesized 
with the First Strand cDNA Synthesis Kit after the measurement of RNA 
concentration. Then, 10 ng of cDNA was used as a template to perform 
semi-quantitative RT-PCR by using Biozym Ready Mix. Details of primer used are 
provided in Table 2.5. Afterward, 1.5% agarose gel electrophoresis and ethidium 
bromide were utilized to separate and visualize the PCR products. Moreover, the 
pUC19/Msp1 marker was used as a size reference. Internal control was GAPDH. The 
data obtained was quantified using the ImageJ software (NIH, Bethesda, MD, USA). 
Table 2.5: Summary of primers sequences and PCR conditions for the genes. 
 
Statistics  
Graph Pad Prism software (El Camino Real, CA, USA) was used for statistical 
analyses. Results are expressed as bar or line diagrams (mean ± SEM). All the 
experiments were performed at least 3 times (N≥3) and measured as triplicates or 
more (n≥3). Data were analyzed by Mann–Whitney U-test or Kruskal–Wallis H test 
followed by a Dunn’s test. Minimum level of significance: p ≤ 0.05. The statistical 
analyses were advised by PD Dr. Sabrina Ehnert. 
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Chapter 3 
3. Result  
3.1. Comparison of 3-D culture and 2-D monolayer culture of primary human 
chondrocytes 
Firstly, in order to establish the optimal model for chondrocyte cell culture, we 
compared different cell culture methods, namely 3-D pellet (Fig. 3.1.a), 2-D 
monolayer (Fig. 3.1.b) and knitted titanium scaffold (Fig. 3.1.c) culture. Viability, 
matrix formation and function of chondrocytes in these culture methods were 
evaluated to decide the optimal model. As shown in the table (Fig 3.1.d), 2-D 
monolayer culture has the advantage of simplicity and ease of operation compared 
with 3-D culture. 
 
Figure 3.1 Comparison of 3-D culture and 2-D monolayer culture of primary 
human chondrocytes. (a) Morphology and size of primary human chondrocytes in 
pellet culture and (b) morphology of primary human chondrocytes in monolayer 
culture after 24 h. (c) Illustration of chondrocytes seeded on the knitted titanium 
scaffolds after 24 h. Calcein-AM was used to show the living cells in the scaffold. The 
black arrowhead indicates the pellet. Different experimental methods were compared 
and listed in the table (d). Tick (√) means the method is available and cross (x) means 
the method is not available. 
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3.2. CSE exposure induces the reduction in viability of primary human 
chondrocytes after 24 h 
Afterward, in order to assess the toxicity of CSE on the chondrocytes, cells were 
exposed to the CSE with increasing concentrations (0.1, 0.5, 1, 5, 10, 20, 50%) for 24 
h. Mitochondrial activity (Fig. 3.2.a) and total protein content (Fig. 3.2.b) were used 
to determine the viability of cells after 24 h incubation (Chen et al., 2020), 
respectively. Mitochondrial activity (20%, **p ≤ 0.01 and 50%, ***p ≤ 0.001) and 
total protein content (20% and 50%, ***p ≤ 0.001) of chondrocytes were significantly 
reduced in the concentrations of CSE over 20% compared to the control group. 
Similarly, the number of living cells was significantly reduced by 20% CSE, as 
determined by Calcein-AM staining (Fig. 3.2.c). 
 
Figure 3.2 CSE exposure induces the reduction in viability of primary human 
chondrocytes after 24 h. After 24 h, (a) Resazurin conversion and (b) SRB staining 
were performed for cell viability. (c). Representative microscopic images for 
Calcein-AM staining. Cells were visualized with Calcein-AM (green) and Hoechst 
33342 (blue) for living cells and nuclear, respectively. Data are presented as bar 
diagrams (mean ± SEM); analyzed by Kruskal–Wallis H test. *p ≤ 0.05, **p ≤ 0.01, 
***p ≤ 0.001 as compared to the control group. Scale bar = 1000 µm. 
 
3.3. Comparison of the effect of CSE exposure twice a week and once a day on 
the primary human chondrocytes 
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For the next step, in order to determine the optimal smoking condition, we compared 
two different exposure pathways to chondrocytes, namely, exposing twice a week  
(Fig. 3.3.a, b, c) and once a day (Fig. 3.3.d, e, f). Cells were exposed to increasing 
concentrations of CSE (0.1, 0.5, 1, 5, 10%) and stopped on days 1, 3, 7 and 14, 
respectively. On day 3 and day 7, mitochondrial activity (Fig. 3.3.a) and total protein 
content (Fig. 3.3.b) of chondrocytes were not affected significantly by exposure to 
CSE twice a week, which was consistent with Calcein-AM staining (Fig. 3.3.c) on 
day 7. On day 14, however, CSE exposure significantly decreased the mitochondrial 
activity (Fig. 3.3.a, 5% and 10%, **p ≤ 0.01 and ***p ≤ 0.001, respectively) and total 
protein content (Fig. 3.3.b, 0.5%, **p ≤ 0.05 and 1%, 5%, 10%, **p ≤ 0.01) of 
chondrocytes compared to the control group. Nevertheless, on day 3, mitochondrial 
activity (Fig. 3.3.d) and total protein content (Fig. 3.3.e, 10%, **p ≤ 0.01) of 
chondrocytes were inhibited significantly by exposing to CSE once a day. On days 7 
and 14, CSE-exposed chondrocytes showed a strong reduction in mitochondrial 
activity (Fig. 3.3.d, 5% and 10%, **p ≤ 0.01) and total protein content (Fig. 3.3.e, 5% 
and 10%, ***p ≤ 0.001), respectively. Similarly, the number of living cells was 
decreased by CSE in a dose-dependent manner on day 7, as determined by 
Calcein-AM staining (Fig. 3.3.f). Therefore, CSE exposure every day is more 
pronounced than exposure twice a week. Based on the above, chondrocytes exposed 
to CSE once a day were selected for further experiments. 
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Figure 3.3 Comparison of the effect of CSE exposure twice a week and once a 
day on the primary human chondrocytes. On days 1, 3, 7 and 14, (a) Resazurin 
conversion and (b) SRB staining were performed for cell viability. (c). Representative 
microscopic images for Calcein-AM staining. Cells were visualized with Calcein-AM 
(green) and Hoechst 33342 (blue) for living cells and the corresponding nuclei, 
respectively. Data are presented as bar diagrams (mean ± SEM); analyzed by 
Kruskal–Wallis H test. *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001, ****p ≤ 0.0001 as 
compared to the control group. Scale bar = 1000 µm. 
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3.4. CSE exposure inhibits the accumulation of ECM in primary human 
chondrocytes 
Aggrecan and collagen II are major components of ECM and can be stained 
specifically by Alcian blue and Safranin-O staining (Akkiraju and Nohe, 2015). We 
performed Alcian blue and Safranin-O staining to investigate the effect of CSE on the 
functionality of primary human chondrocytes. CSE-exposed chondrocytes showed a 
dose-dependent decline in matrix accumulation on day 7 (Fig 3.4.a, 10%, ***p ≤ 
0.001) and day 14 (Fig. 3.4.b, 5% and 10%, **p ≤ 0.01 and ***p ≤ 0.001, 
respectively), respectively. Similarly, the stains of Alcian blue (Fig 3.4.c) and 
Safranin-O (Fig 3.4.d) dye were decreased on day 7, respectively.  
 
Figure 3.4 CSE exposure inhibits the accumulation of ECM in primary human 
chondrocytes. Matrix formation was quantified on day 7 (a) and day 14 (b) by Alcian 
blue staining. Representative microscopic images for Alcian blue (c) and Safranin-O 
(d) staining were performed on day 7. Data are presented as bar diagrams (mean ± 
SEM); analyzed by Kruskal–Wallis H test. **p ≤ 0.01, ***p ≤ 0.001 as compared to 
the control group. Scale bar = 400 µm. 
 
3.5. CSE exposure down-regulates the anabolic gene expression of primary 
human chondrocytes 
Since after 7 days of treatment with CSE, the matrix accumulation of chondrocytes 
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was inhibited significantly by 10% CSE, we wanted to know whether the inhibition 
was due to the down-regulation of gene expression. On day 7, the mRNA expression 
analysis showed that Collagen II (Fig. 3.5.a, **p ≤ 0.01), a major component of ECM 
protein (Archer, 2003), was significantly down-regulated to 0.2-fold in 10% 
CSE-exposed group. Similarly, gene expression of Aggrecan (Fig. 3.5.b, **p ≤ 0.01), 
an ECM marker for cartilage(Archer, 2003), and SOX-9 (Fig. 3.5.c, **p≤ 0.01), which 
is the main transcription factor for particularization and sustentation of cartilage (Tew 
et al., 2008), was significantly suppressed to 0.5-fold and 0.75-fold, respectively. 
Intriguingly, gene expression of Collagen X (Fig. 3.5.d), a marker of hypertrophic 
chondrocyte (Nejadnik et al., 2015), was not affected by 10% CSE. Therefore, CSE 
exposure negatively affected the anabolic gene expression (Collagen II, Aggrecan and 
SOX-9) of chondrocytes, which might interrupt the formation of the chondrocyte 
matrix and result in cartilage demolishment. 
 
Figure 3.5 CSE exposure down-regulates the anabolic gene expression of 
primary human chondrocytes. Semi-quantitative RT-PCR was performed using 
primers for gene expression. The gene expression of (a) Collagen II, (b) Aggrecan, (c) 
Sox9, and (d) Collagen X was normalized to the GAPDH (housekeeping gene). Data 
are presented as bar diagrams (mean ± SEM); analyzed by Mann Whitney test. **p ≤ 
0.01 as compared to the control group. 
 
3.6. CSE exposure increases oxidative stress and accelerates the death of primary 
human chondrocytes 
It is believed that ROS in or induced by CS is one of the critical risk factors in 
producing adverse effects on the human body (Kamceva et al., 2016, Chen et al., 
2020). The production of ROS was increased when chondrocytes were exposed to 
37 
 
CSE at the concentration of 1% and above, and 10% CSE induced significantly high 
amounts of ROS (2-fold) as compared to corresponding untreated cells, (Fig. 3.6.a, 
**p ≤ 0.01). Meanwhile, the death of chondrocytes occurs during the process of OA 
and is connected with the accumulation of ECM (Valavanidis A et al., 2009, Thomas 
et al., 2007). Increased oxidative stress is known to induce cell death (Collins et al., 
2016, Chen et al., 2020). Therefore, it is interesting to assay whether the CSE could 
induce chondrocyte cell death through the generation of ROS production. Incubation 
of chondrocytes with 10% CSE for 3 days showed an increase in dead cells and a 
decrease in living cells, and treatment of chondrocytes with 0.01% hydrogen peroxide 
for 20 min, which represents a principal ROS in cigarette smoke (Valavanidis A et al., 
2009, Chen et al., 2020), significantly induced cell death of chondrocytes (Fig. 3.6.b), 
thus associating the high ROS production by CSE with the increase of cell death in 
chondrocytes.  
 
Figure 3.6 CSE exposure increases oxidative stress and accelerates the death of 
primary human chondrocytes. (a). ROS production was measured by DCFH-DA 
assay. (b). Living cells (green) and dead cells (red) were visualized by Calcein AM 
and ethidium homodimer, respectively (Representative figure for day 3. H2O2 (0.01% 
V/V) was performed as a positive control. Data are presented as line diagrams (mean ± 
SEM); analyzed by Kruskal–Wallis H test. **p ≤ 0.01, ****p ≤ 0.0001 as compared 
to the control group. Scale bar = 400 µm. 
 
3.7. Clinical doses of Dex are toxic to the primary human chondrocytes 
Steroid injections, such as hydrocortisone, Dex, and methylprednisolone, have been 
frequently and successfully used in alleviating joint symptoms and inhibiting 
inflammation (Wernecke et al., 2015, Chen et al., 2020). CSs act both immune- 
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suppressive and anti-inflammatory (Huebner et al., 2014). Besides, it is also reported 
that CSs could inhibit ROS generation (Dandona et al., 1999, Chen et al., 2020). On 
the other hand, many preliminary studies reported the adverse effects of Dex on 
cartilage integrity and chondrocyte viability (Tu et al., 2013, Zhao et al., 2014). In 
order to test the non-toxic concentrations of Dex to the chondrocytes, cells were 
treated with a series of doses of Dex (4-4000 μg/ml) for 24 h, in which clinical dosage 
(4000 μg /ml) was included (JR, 1996, Grodzinsky et al., 2017, Chen et al., 2020). 
Mitochondrial activity (Fig. 3.7.a, ≥ 1000 μg/ml, ****p ≤ 0.0001) and total protein 
content (Fig. 3.7.b, 2000 μg/ml and 4000 μg/ml, **p ≤ 0.01 and ***p≤ 0.001, 
respectively) showed a dose-dependent inhibition in Dex-treated chondrocytes, 
suggesting detrimental effects of Dex on chondrocytes (Chen et al., 2020). 
 
Figure 3.7 Clinical doses of Dex are toxic to the primary human chondrocytes. 
After 24 h, (a) Resazurin conversion and (b) SRB staining were performed for cell 
viability. Data are presented as line diagrams (mean ± SEM); analyzed by 
Kruskal–Wallis H test. **p ≤ 0.01, ***p ≤ 0.001, ****p ≤ 0.0001 as compared to the 
untreated controls. 
 
3.8. Clinical doses of HA increases the viability of primary human chondrocytes 
HA is the main component of cartilage ECM and synovial fluid in both healthy and 
OA joints (Akmal M, 2005, Temple-Wong et al., 2016, Chen et al., 2020). It is used 
with IA injection and is extensively recommended in most guidelines ( Wernecke et 
al., 2015, Baron et al., 2018) as a visco-supplementation, owing to HA concentration 
is decreased in the synovial liquid of pathologic joints compared with healthy joints 
(Akmal M, 2005, Temple-Wong et al., 2016, Chen et al., 2020). In addition to its role 
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in visco-supplementation, an important biological aspect of HA is its benefits to the 
chondrocytes, such as chondro- protection (Akmal M, 2005), scavenging of reactive 
oxygen-derived free radicals (Yu et al., 2014) and inhibition of inflammation 
(Fioravanti et al., 2005). In order to determine the non-toxic concentrations of HA to 
the chondrocytes, cells were treated with HA (0.1–5 mg/ml) for 24 h, in which 
clinical dosage (5 mg/ml) was included (Trueba Davalillo et al., 2015, Chen et al., 
2020). Mitochondrial activity (Fig. 3.8.a) and total protein content (Fig. 3.8.b, 5 
mg/ml, ***p ≤ 0.001) showed a dose-dependent improvement of cell growth in 
HA-treated chondrocytes, indicating the applied clinical doses of HA are beneficial to 
the primary human chondrocytes. 
 
Figure 3.8 Clinical doses of HA increases the viability of primary human 
chondrocytes. After 24 h, (a) Resazurin conversion and (b) SRB staining were 
performed for cell viability. Data are presented as line diagrams (mean ± SEM); 
analyzed by Kruskal–Wallis H test. ***p ≤ 0.001 as compared to the untreated group. 
 
3.9. Cytotoxicity assessment of Vitamin C on the primary human chondrocytes 
Vitamin C, also known as ascorbic acid (AA), has been extensively applied in 
orthopedic applications for its role in wound healing (Bikker et al., 2016), bone 
formation (Aghajanian et al., 2015) and chondro-protection (Chiu et al., 2016). 
Furthermore, AA is also a robust antioxidant and cofactor, which provides protection 
against oxidative stress and regulates cellular development (Graeser et al., 2009). 
Several studies have demonstrated that AA supplementation has the potential to 
inhibit the degeneration of chondrocyte morphology and biochemistry (Ibold et al., 
2009, Stabler and Kraus, 2003). These findings suggest that AA may be a promising 
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drug or antioxidant in protecting oxidative stress damaged chondrocyte. In order to 
evaluate the concentrations that were non-toxic to the chondrocytes, cells were treated 
with a series of concentrations of AA (50 µM − 10 mM) for 24 h. Mitochondrial 
activity (Fig. 3.9.a, 10 mM, ****p ≤ 0.0001) and total protein content (Fig. 3.9.b) 
showed that the concentrations of AA over 1 mM were toxic to the chondrocytes.  
 
Figure 3.9 Cytotoxicity assessment of Vitamin C on the primary human 
chondrocytes. After 24 h, (a) Resazurin conversion and (b) SRB staining were 
preformed for cell viability. Data are presented as line diagrams (mean ± SEM); 
analyzed by Kruskal–Wallis H test. *p ≤ 0.05, **p ≤ 0.01, *****p ≤ 0.0001 as 
compared to the untreated group. 
 
3.10. Effects of AA on the CSE-exposed primary human chondrocytes 
Subsequently, three concentrations of AA (50, 100, 200 µM) were performed in the 
following experiments. Mitochondrial activity (Fig. 3.10.a, 50, 100, 200 µM, ***p ≤ 
0.001), total protein content (Fig. 3.10.b, 50, 100, 200 µM, ****p ≤ 0.0001), and 
matrix formation were increased (Fig 3.10.c, 50 µM, **p ≤ 0.01 and 100, 200 µM, *p 
≤ 0.05) when the cells were solely incubated with AA on day 7. However, 
mitochondrial activity (Fig. 3.10.a, 200 µM, °°°°p ≤ 0.0001), total protein content 
(Fig. 3.10.b, 200 µM, °°p ≤ 0.01) and matrix formation showed a dose-dependent 
decrease (Fig. 3.10.c; 200 µM, °°p ≤ 0.01) when the chondrocytes were co-incubated 
with CSE and AA on day 7. 
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Figure 3.10 Effects of AA on the CSE-exposed primary human chondrocytes. On 
day 7 of treatment, (a) Resazurin conversion and (b) SRB staining were performed for 
cell viability. Matrix accumulation was quantified by (c) Alcian blue staining. Data 
are presented as bar diagrams (mean ± SEM); analyzed by Kruskal–Wallis H test. *p 
≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001, ****p ≤ 0.0001 vs. the untreated group, °°p ≤ 
0.01, °°°°p ≤ 0.0001 as indicated. 
 
3.11. Evaluation of low doses of Dex and HA on the CSE-impaired primary 
human chondrocytes 
HA injection is used to improve the functional mobility of pathologic OA joints, since 
HA is capable of improving viscoelastic properties to the synovial liquid 
(Temple-Wong et al., 2016, Chen et al., 2020). In addition to its role in 
viscosupplementation, an important biological aspect of HA is its benefits to the 
chondrocytes, such as chondro- protection (Akmal M, 2005), scavenging of reactive 
oxygen-derived free radicals (Yu et al., 2014) and inhibition of inflammation 
(Fioravanti et al., 2005). Subsequently, we attempted to evaluate whether the 
detrimental effects of CSE on cells could be retrieved by HA or low doses of Dex. 
Three different concentrations of HA (0.1, 1, 5 mg/ml) and Dex (4, 40, 400 μg/ml) 
based on the above data were chosen for the following experiments. On day 7, a 
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dose-dependent decrease in mitochondrial activity (Fig. 3.11.a, 400 μg/ml, **p ≤ 
0.01), total protein content (Fig. 3.11.b, 400 μg/ml, **p ≤ 0.01) and matrix formation 
(Fig. 3.11.c, 400 μg/ml, **p ≤ 0.01) was observed in Dex-treated chondrocytes. 
Interestingly, there was no differential variation was observed when CSE-impaired 
cells were incubated with Dex for 7 days. On day 14, AP activity increased 
significantly (Fig. 3.11.d, 4μg/ml, *p ≤ 0.05, 40μg/ml, **p ≤ 0.01 and 400 μg/ml, **p 
≤ 0.01) in the Dex-treated cells, indicating that Dex was prone to modifying the 
morphology of chondrocytes after long-term treatment. In contrast to Dex, a 
significant increase in mitochondrial activity (Fig. 3.11.e, 1 mg/ml and 5 mg/ml, °°p ≤ 
0.01 and °°°°p ≤ 0.0001, respectively) and total protein content (Fig. 3.11.f, 5 
mg/ml, °°°°p ≤ 0.0001) was observed after HA exposure of CSE-impaired cells after 
7 days. Besides, the accumulation of chondrocyte matrix was enhanced significantly 
(Fig. 3.11.g, 1 mg/ml, °p ≤ 0.05 and 5 mg/ml, °p ≤ 0.05) on day 7. 
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Figure 3.11 Evaluation of low doses of Dex and HA on the CSE-impaired 
primary human chondrocytes. On day 7 of treatment, (a, e) Resazurin conversion 
and (b, f) SRB staining were performed for cell viability. Matrix accumulation was 
quantified by (c, g) Alcian blue staining. (d). AP activity was measured on day 7 and 
day 14, respectively. Data are presented as bar and diagrams (mean ± SEM); analyzed 
by Kruskal–Wallis H test. *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001, ****p ≤ 0.0001 vs. 
the untreated group, °p ≤ 0.05, °°°p ≤ 0.001 as indicated. 
 
3.12. Effects of Ace and Dic on the CSE-impaired primary human chondrocytes 
Severe adverse effects of oral analgesic/anti-inflammatory agents, like Ace and 
NSAIDs, led to the emergence of IA injections of these drugs, which proved to be 
effective in suppressing inflammation and alleviating pain in joints (Arun et al., 2013, 
Cannava et al., 2013, Mertz et al., 2016). Considering OA is a chronic disabling 
disease, pharmacological treatments would require a prolonged time-span (Chen et al., 
2020). We evaluated the effects of Ace (10 μg/ml) and Dic(1 μg/ml) on the 
CSE-impaired chondrocytes, showing that these drugs did not promote the 
detrimental effects of CSE on the mitochondrial activity (Fig 3.12.a) and the total 
protein content (Fig 3.12.b) of chondrocytes on day 7. Similarly, matrix formation of 
CSE-impaired chondrocytes was unaffected by Ace and Dic (Fig 3.12.c). 
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Figure 3.12 Effects of Ace and Dic on the CSE-impaired primary human 
chondrocytes. On day 7 of treatment, (a) Resazurin conversion and (b) SRB staining 
were performed for cell viability. Matrix accumulation was quantified by (c) Alcian 
blue staining. Data are presented as bar diagrams (mean ± SEM); analyzed by Mann 
Whitney test. ****p ≤ 0.0001 vs. the untreated group, °p ≤ 0.05, °°p ≤ 0.01, °°°p ≤ 
0.001 as indicated. 
 
3.13. Evaluation of HA combined with anti-inflammatory drugs on the 
CSE-impaired chondrocytes 
Lastly, we investigated the effects of HA combined with Dic (1 μg/ml), Ace (10 
μg/ml) or low dose of Dex (4 μg/ml) on CSE-impaired chondrocytes. On day 7 of 
treatment, the groups of HA + Dic and HA + Ace significantly increased 
mitochondrial activity (Fig. 3.13.a, HA+Dic and HA+Ace, °°°p ≤ 0.001), and matrix 
accumulation (Fig. 3.13.c, HA+Dic and HA+Ace, °p ≤ 0.05, °°p ≤ 0.01, respectively) 
in CSE-impaired chondrocytes when compared with 10% CSE-exposed chondrocytes 
without treatment. Although HA combined with Dex did not significantly increase the 
mitochondrial activity and matrix accumulation in CSE-impaired chondrocytes, a 
slight increase trend was observed. All HA combination groups significantly 
promoted the total protein content (Fig. 3.13.b, HA+Dex and HA+Dic, °°p ≤ 0.01, 
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HA+Ace, °°°p ≤ 0.001) of CSE-exposed chondrocytes, bringing it up to nearly the 
level of chondrocytes unexposed to CSE. The generation of ROS was suppressed by 
HA alone and HA combinatory treatments (Fig. 3.13.d, HA+Dex and HA+Dic, °°p ≤ 
0.01, HA+Ace, °°°p ≤ 0.001), indicating that HA alone and HA combinatory 
treatments retrieved the chondrocyte impairment caused by CSE through suppressing 
and/or quenching the production of ROS. 
 
Figure 3.13 Evaluation of HA combined with anti-inflammatory drugs on the 
CSE-impaired chondrocytes. On day 7 of treatment, (a) Resazurin conversion and 
(b) SRB staining were performed for cell viability. Matrix accumulation was 
quantified by (c) Alcian blue staining. (d). ROS production was measured by 
DCFH-DA assay. H2O2 (0.01% V/V) was performed as a positive control. Data are 
presented as bar diagrams (mean ± SEM); analyzed by Kruskal–Wallis H test. *p ≤ 
0.05, **p ≤ 0.01, ***p ≤ 0.001，****p ≤ 0.0001 vs. the untreated group, °p ≤ 0.05, °°p 
≤ 0.01, °°°p ≤ 0.001 as indicated. 
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Chapter 4 
4. Discussion  
CS is a poisonous and carcinogenic combination, which more than 5,000 chemicals 
and at least 55 carcinogens are involved (Talhout et al., 2011, Chen et al., 2020). 
Several preclinical and clinical studies have demonstrated the detrimental effects of 
CS in musculoskeletal disorders (Sreekumar et al., 2017, Ehnert et al., 2019, Chen et 
al., 2020). However, the association between CS and symptomatic OA is still unclear. 
Racunica et al. demonstrated that tibial cartilage volume was increased in smokers, 
but tibiofemoral cartilage defects were not present (Racunica et al., 2007). In a 
cross-sectional study, Kang et al. found that there was a weak association between 
indirect smoking and the prevalence of knee OA, while direct and former smoking 
was not associated with OA prevalence (Kang et al., 2016). On the contrary, the 
finding of Davies-Tuck and colleagues suggested that smoking was associated with 
increased medial knee cartilage loss (medial: difference=13.4 µl, P=0.03). In addition, 
a positive relationship between pack-year (PY) smoked and the loss of medial 
cartilage bulk was also observed (P=0.04) (Davies-Tuck et al., 2009). Similarly, Amin 
et al. found that male smokers with knee OA suffered the greater risk of cartilage loss 
as well as more severe pain than non-smokers (Amin et al., 2007). Nevertheless, these 
studies are only based on the radiographic images (MRI, X-ray) or post-operative 
outcome, and no direct research yet has evaluated the effects of CS on human 
cartilage or primary human chondrocytes. Thus, these results may be not conclusive, 
since the structural changes of cartilages within the smoker’s joints are still not known 
(Chen et al., 2020). Ying et al. (Ying et al., 2012) and Gullahorn et al.(Gullahorn et 
al., 2005) reported that nicotine increased proliferation, collagen synthesis, as well as 
gene and protein expression of chondrocytes from both normal human and OA 
patients. Nevertheless, cigarettes contain plenty of toxins, such as nicotine, cotinine, 
carbon monoxide and tar (Talhout et al., 2011). Toxins involved in tobaccos have 
been shown to increase oxidative stress (Kamceva et al., 2016, Chen et al., 2020), 
inflammatory responses (Barua et al., 2015), or hypoxia (Fricker et al., 2018), which 
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all could lead to cartilage damage. Recently, we have reported that CSE could damage 
the TGF-β signaling pathway and negatively affect migration, proliferation, and 
chondrogenesis of MSCs (Aspera-Werz et al., 2019). However, it is still unknown 
how cigarette smoke affects human cartilage and primary chondrocytes.Chondrocytes 
are derived from MSCs and exclusively found in AC, they possess the properties of 
proliferating and synthesizing ECM to maintain the functionality and integrity of AC 
(Sophia Fox et al., 2009, Chen et al., 2020). Chondrocytes lose their phenotype and 
dedifferentiate when they are expanded on conventional 2D culture surfaces (Babur et 
al., 2013), and this shift is activated both by morphological changes and by alteration 
in gene expressions (Schnabel et al., 2002). In this context, pellet culture and 
biomaterial-based scaffold, supplemented with or without various growth factors 
(TGF-ß, BMP, FGF-2), were developed to avoid chondrocyte dedifferentiation 
(Solchaga et al., 2011, Herlofsen et al., 2011). In our previous studies, a high 
biocompatible knitted titanium scaffold was utilized as a pattern of the 3D cell culture 
method in intervertebral disc (IVD) treatment (Tendulkar et al., 2019). Thus, we 
compared these three different methods (monolayer culture, pellet culture, and 
scaffold) to establish an optimal cell culture method for chondrocytes. We found that 
the traditional 2D monolayer culture had the advantages of simplicity and ease of 
operation compared with 3D culture in our lab.  
Nicotine is known as the primarily pharmacologically active and addictive component 
involved in smoking (Benowitz et al., 2009). The levels of nicotine in the blood 
plasma can reach to 100 ng/ml gradually after smoking a cigarette, but usually 
fluctuate between 20 and 60 ng/ml (Benowitz et al., 2009). The plasma half-life of 
nicotine averages about 2 h after cigarette smoking (Benowitz et al., 1988). Moreover, 
the concentrations of nicotine in skeletal muscle are in line with those of whole blood. 
In our study, the concentrations of CSE were correspond to the nicotine concentration 
in the cigarettes (Sreekumar et al., 2017). In addition, among “smokers,” the smoking 
history for patients can differ from a few cigarettes a day for a few years to packs of 
cigarettes daily for decades (Janjigian et al., 2010). In order to mimic this situation, 
we compared two different exposure pathways to chondrocytes, namely, exposing 
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twice a week and once a day. We found that CSE exposure every day is more 
pronounced than that of twice a week.  
In our study, we observed an inhibited effect of CSE on the metabolic activity of 
primary human chondrocytes. However, the mechanisms leading to these detrimental 
effects are still unknown. Thus, we subsequently attempt to investigate how CSE 
negatively affected chondrocytes. It is believed that oxidative stress induced by CS is 
one of the critical risk factors in producing adverse effects on the human body. 
Kamceva and co-workers reported that smoking is a key factor in promoting oxidative 
stress and inhibiting antioxidant defense in Coronary Artery Disease (CAD) patients, 
and the number of cigarettes smoked was positively associated with the level of 
oxidative damage (Kamceva et al., 2016). Recently, we have reported that nicotine 
and cotinine led to the accumulation of ROS by impairing antioxidant defense activity 
in bone cells, although they did not directly produce ROS (Aspera-Werz et al., 2018). 
In our study, ROS production of chondrocytes was significantly elevated in culture 
supernatants following an exposure of 10% CSE, which corresponds to smoking 
approximately one pack cigarettes/day (Aspera-Werz et al., 2019, Chen et al., 2020). 
Considering that chondrocytes are quiescent cells and only proliferate under 
pathological conditions, the survival of chondrocytes is crucial for the functionality 
and integrity maintenance of AC (Charlier et al., 2016, Chen et al., 2020). 
Furthermore, the death of chondrocytes occurs during the process of OA and is 
connected with the accumulation of ECM (Thomas et al., 2007). Collins et al. 
reported that pro-death signaling pathways in chondrocytes could be initiated by 
increased oxidative stress, resulting in cell death and consequently compromising the 
integrity of AC (Collins et al., 2016). Therefore, we hypothesized that CS would 
induce chondrocyte cell death by increasing oxidative stress. We found that 10% CSE 
and 0.01% hydrogen peroxide (a principal ROS in cigarettes) equally caused a 
significant growth in the number of dead cells, thus linking the increased oxidative 
stress by CSE to the induction of cell death in chondrocytes. However, multiple 
modes are involved in the chondrocyte cell death, including apoptosis (Hwang and 
Kim, 2015), necrosis (Chen et al., 2001), autophagy (Chang et al., 2013), or a 
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combination of these processes (Almonte-Becerril et al., 2010). In the future, it is 
necessary to investigate which form of death occurs in the CSE-induced chondrocytes 
(Chen et al., 2020). 
Vitamin C, also known as L-ascorbic acid (AA), has been extensively applied in 
orthopedic applications for its role in wound healing (Bikker et al., 2016), bone 
formation (Aghajanian et al., 2015) and chondro-protection (Huang et al., 2018). 
Furthermore, AA is also a robust antioxidant and cofactor, which provides protection 
against oxidative stress and regulates cellular development (Chiu et al., 2016). Several 
studies have demonstrated that AA supplementation is able to inhibit the degeneration 
of chondrocyte morphology and biochemistry (Chiu et al., 2016, Chang et al., 2015). 
These findings suggest that AA may be a promising drug or antioxidant in protecting 
oxidative stress damaged chondrocyte. Furthermore, smokers showed lower AA 
concentrations in blood plasma than those of nonsmokers (Kelly, 2003, Smith and 
Hodges, 1987). Therefore, higher daily consumption of AA is required for smokers to 
reach the normal plasma concentration, owing to their elevated metabolic rate and 
defective AA recycling (Smith and Hodges, 1987, Schectman, 1993). In our study, 
AA inhibited the metabolism of chondrocytes co-incubated with CSE, resulting in a 
decreased viability and matrix formation on day 7. The concentrations of AA used in 
our study were lower than the peak concentration (200 μM) of AA that can be 
obtained by oral administration (AA 3 g every day 4 h administrated orally) 
(Padayatty et al., 2004), suggesting that AA supplementation was not an appropriate 
treatment for smokers with OA. 
IA injections of CSs, such as hydrocortisone, dexamethasone (Dex), and 
methylprednisolone, have been frequently used in alleviating joint symptoms and 
inhibiting inflammation, and their efficacy has been evaluated in many preclinical and 
clinical trials (Zhang et al., 2008, Grodzinsky et al., 2017, Stove et al., 2002). Former 
studies have demonstrated the advantageous effects of Dex on suppressing 
pro-inflammatory cytokine accumulation, such as IL-1β, in the affected joint 
(Huebner et al., 2014, Chen et al., 2020). Besides, it is reported that Dex unleashes 
immune-suppression and anti-inflammation by means of suppressing the generation 
50 
 
of ROS production (Dandona et al., 1999, Chen et al., 2020). However, the negative 
effects of these drugs on AC remain a concern, and many guidelines suggest that it 
should be used with caution (Grillet and Dequeker, 1990, Chen et al., 2020). Many 
preliminary studies also reported the adverse effects of Dex on cartilage integrity and 
chondrocyte viability (Song et al., 2012, Su et al., 1996). Our study showed that 
clinical doses of Dex were noxious to chondrocytes, and lower doses seemed to be 
nontoxic (Chen et al., 2020). Results of our present study are similar to findings by 
Busse et al., showing that Dex with diluted concentrations has minor effects on the 
viability of primary human chondrocytes (Busse et al., 2019, Chen et al., 2020). In 
addition, our study found that treatment with Dex for 14 days significantly increased 
the AP activity of primary human chondrocytes, suggesting that Dex might modify 
the function of chondrocyte after long-term exposure. Similarly, Stewart and 
colleagues reported that AP activity and AP mRNA were increased when the equine 
MSCs treated with Dex, resulting in cells differentiation toward bone (Stewart et al., 
2008, Chen et al., 2020). In summary, the beneficial effects of IA injection of Dex 
occur at low doses and short-time treatment duration. Therefore, for clinical 
application in smokers with OA, several factors such as indication, dose, and 
treatment duration should be taken into consideration.  
HA, also called hyaluronan, is a form of polyanionic, nonsulfated glycosaminoglycan 
with high molecular weight (Sirin et al., 2018). In the clinic, it is used with IA 
injection to improve the functional mobility of pathologic OA joints, since HA is 
capable of improving viscoelastic properties to the synovial liquid (Temple-Wong et 
al., 2016, Chen et al., 2020). In addition to its role in viscosupplementation, an 
important biological aspect of HA is its benefits to the chondrocytes, such as chondro- 
protection (Akmal M, 2005), scavenging of reactive oxygen-derived free radicals (Yu 
et al., 2014) and inhibition of inflammation (Fioravanti et al., 2005). The volume of 
synovial fluid in most of the knee joints is around 0.5-4.0 ml, and the pH is between 7 
and 8 (Kraus et al., 2007). In general, IA injections of HA (2-3 ml) with a 
concentration of 10 mg/ml are used in treating the affected joints (Concoff et al., 2017, 
Chen et al., 2020). According to that, the dilution of HA with synovial fluid is 
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approximately 1:2 (Chen et al., 2020). In our study, high doses of HA (2.5 mg/ml and 
5.0 mg/ml) promoted the viability and matrix accumulation of CSE-impaired 
chondrocytes. On the contrary, Akmal et al. found that HA had a beneficial effect on 
the metabolic activity of bovine articular chondrocytes in low doses (0.1 mg/ml and 
1.0 mg/ml) (Akmal M, 2005, Chen et al., 2020). It is likely that CSE down-regulated 
the expression of CD44 (a HA receptor at the chondrocyte cell surface) and limited 
the interaction of chondrocytes with their surrounding ECM (Responte et al., 2012), 
resulting in a decreased cell response to HA (Chen et al., 2020). 
In the past decades, oral NSAIDs or Ace have been widely used for relieving pain in 
OA patients (Ringdahl E, 2011, Sostres et al., 2010) and recommended as the 
first-line pain medication for OA by most guidelines (Hunter and Bierma-Zeinstra, 
2019, Dougados, 2006). However, limited delivery to the inflamed joints 
(Wongrakpanich et al., 2018) and side effects regarding gastrointestinal and 
cardiovascular complications of oral administration (Sostres et al., 2010, McGill and 
Jaeschke, 2014) restrict their efficacy and application. These limitations have hence 
led to the emergence of IA injections of these drugs, which proved to be effective in 
suppressing inflammation and alleviating pain in joints (Arun et al., 2013, Cannava et 
al., 2013, Mertz et al., 2016). Considering OA is a chronic disabling disease, 
pharmacological treatments would require a prolonged time-span (Chen et al., 2020). 
Additionally, the nature of short biological half-life of Ace (approx 3 h) (Hodgman 
and Garrard, 2012) and Dic (approx 2 h) (Miyatake et al., 2009) requires frequent 
injections to obtain effective concentration (Chen et al., 2020). Therefore, we used 
these drugs with identical therapeutic levels observed in plasma and exposed primary 
human chondrocytes to them every day. We found that therapeutic doses of Dic (1 
μg/ml) and Ace (10 μg/ml) did not augment the detrimental effects of CSE on the 
overall metabolism of chondrocytes (viability, proliferation, and matrix accumulation). 
Similarly, in the findings of Blot et al., 0.3−3 μg/ml of Dic unaffected the synthesis of 
proteoglycan and HA within the cartilages of moderate and severe OA (Blot et al., 
2000). Qi et al. and Arun et al. found that IA injection of Dic had analgesic and 
anti-inflammatory effects on rats (Qi et al., 2016, Arun et al., 2013), indicating their 
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possibility for IA injection. Accordingly, IA injections of NSAIDs and Ace would be a 
promising alternative for Dex and might delay joint deterioration in smokers with OA. 
It is critical to note that OA is a chronic disease that affects the whole joint, involving 
cartilage breakdown, inflammation, and osteophytes formation (Hunter and 
Bierma-Zeinstra, 2019, Chen et al., 2020). Therefore, in addition to pain alleviation 
and inflammation inhibition should be addressed, another important aspect is cartilage 
repair (Chen et al., 2020). In recent, several studies evaluated the effects of HA 
combined with anti-inflammatory drugs (CSs or NSAIDs) (Siengdee et al., 2015, 
Euppayo et al., 2017), for the sake of developing more effective OA treatments (Chen 
et al., 2020). Euppayo et al. compared the efficacy of IA injection of HA with or 
without anti-inflammatory (AI) drugs (CS or NSAIDs) in OA patients, and found that 
HA combined with AI had greater efficacy than HA alone in terms of pain alleviation 
(Euppayo et al., 2017). We investigated the effects of HA combined with different 
anti-inflammatory drugs (Ace, Dic, and Dex) on CSE-impaired chondrocytes. Our 
results demonstrated that HA combined with Dic, Ace, or low doses of Dex had a 
protective effect on the CSE-exposed chondrocytes, as they significantly inhibited the 
generation of free radicals and promoted the viability and ECM accumulation of cells. 
It is reported that synovial fluid levels of ROS (H2O2 and O2−) and H2O2-induced 
chondrocyte cell death could be suppressed by IA injection of HA (Yu et al., 2014). 
Our present study shows that an inhibition of ROS production with HA or its 
combinations with anti-inflammatory drugs, exhibiting chondro-protective effects by 
scavenging the generation of free radicals (Chen et al., 2020). 
In addition, the detrimental effects of cigarette smoke on chondrocytes in vitro are, at 
least partially, mitigated to the in vivo situation. Therefore, further studies are needed 
to elucidate whether the metabolic changes of cells in vitro would also appear in 
articular cartilage (Chen et al., 2020). Moreover, further in vivo work should be 
performed to determine the optimal drug dose and frequency before clinical 
application (Chen et al., 2020). 
In conclusion, the data presented herein are the first time to evaluate the effects of 
CSE on the metabolisms of primary human chondrocytes. CSE inhibited 
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chondrocytes viability, ECM accumulation, as well as it decreases their anabolic gene 
expression (Collagen II, Aggrecan, Sox9). Oxidative stress was associated with CSE 
and generated when chondrocytes were exposed to it. Increased oxidative stress 
induced chondrocyte cell death. Dex had a dose- and time- dependent negative effect 
on primary human chondrocytes, however, with favorable effects occurring at low 
doses (＜ 400 μg/ml) and short treatment intervals. Clinical dose (4 mg/ml) of Dex 
was toxic to the cells, and long-term duration would modify the function and 
morphology of cartilage. In contrast to Dex, therapeutic doses of Dic (1 μg/ml) and 
Ace (10 μg/ml) did not augment the detrimental effects of CSE on the overall 
metabolisms of chondrocytes. Additionally, a clinical dose of HA (5 mg/ml) or HA 
combined with Dic, Ace, or low doses of Dex had a protective effect on the 
CSE-exposed chondrocytes, as they significantly inhibited the generation of free 
radicals and promoted the viability and ECM accumulation in cell cultures. 
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Chapter 5 
5. Summary 
Although the adverse effects of smoking for human musculoskeletal system have 
been well accepted, less attention has been paid by researchers to the relevance of 
cigarette smoke to the onset of osteoarthritis (OA). Here, we investigated the effects 
of cigarette smoke extract (CSE) on human primary chondrocyte function. In addition, 
we investigated whether the pharmacologic treatment of dexamethasone was 
beneficial to chondrocytes impaired by CSE, and if not, whether it could be 
substituted by other treatments, such as acetaminophen and NSAIDs. Finally, we 
evaluated the effects of hyaluronic acid (HA) and HA combinatory treatments 
(dexamethasone, acetaminophen or diclofenac) on the chondrocytes impaired by CSE, 
in order to determine a potential therapeutic alternative for clinical application to 
smokers undergoing symptomatic OA. 
All human tissues were obtained in accordance with the ethical approval of the 
University Hospital Tübingen and with patients’ written consent. Human primary 
chondrocytes were exposed to increasing concentrations (0%, 0.1%, 0.5%, 1%, 5%, 
10%) of CSE (containing 3.6 ng/ml to 72 ng/ml nicotine and 40 ng/ml to 800 ng/ml 
tar). Cell viability was analyzed by resazurin conversion assay and SRB staining, 
matrix formation was stained using Alcian blue and Safranin-O staining. The 
generation of free radical was evaluated by DCFH-DA assay. Semi-quantitative 
RT-PCR was performed to analyze gene expressions. 
Our present study demonstrated that the mitochondrial activity, total protein content 
and the accumulation of matrix were dose- and time-dependently inhibited by CSE in 
primary human chondrocytes. Moreover, increased oxidative stress led to cell death 
by 10% CSE, which is associated with approximately smoking one pack a day. As an 
anti-inflammatory treatment strategy, traditional pharmacologic therapy with 
dexamethasone (Dex) was evaluated. Clinical doses of Dex were toxic to the cells, 
and long-time incubation with lower doses (4−400 μg/ml) of Dex would lead to a 
hypertrophic chondrocyte phenotype. To substitute dexamethasone, a clinical dosage 
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of diclofenac (Dic) and acetaminophen (Ace) was tested on chondrocytes. 
Interestingly, therapeutic doses of Dic (1 μg/ml) and Ace (10 μg/ml) did not augment 
the detrimental effects of CSE on the overall metabolisms of chondrocytes. 
Additionally, a clinical dose of HA (5 mg/ml) and/or HA combined with Dic, Ace, or 
doses of Dex had protective effects on the CSE-exposed chondrocytes, as they 
significantly inhibited or trap the generation of free radical and promoted the viability 
and ECM accumulation of cells. Our study demonstrates that cigarette smoke induces 
cell death through elevating oxidative stress and demolishes cartilage formation. 
Intra-articular (IA) injection of HA combined with therapeutic doses of 
analgesic/anti-inflammatory agents (Ace or Dic) could reverse the detrimental effects 
of CSE on primary human chondrocytes, thus opening up potential therapeutic 
alternatives in treating smokers to suffering from symptomatic OA. 
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6. Zusammenfassung 
Obwohl mehrere Forscher die schädlichen Auswirkungen des Rauchens auf den 
Bewegungsapparat bestätigt haben, ist der Zusammenhang zwischen Rauchen und 
dem Auftreten von Arthrose (OA) immer noch unklar. Hier untersuchten wir die 
Auswirkungen von Zigarettenrauchextrakt (CSE) auf die primäre 
Chondrozytenfunktion des Menschen. Darüber hinaus wurde getestet, ob die 
pharmakologische Behandlung von Dexamethason für durch CSE beeinträchtigte 
Chondrozyten von Vorteil ist oder ob sie durch andere Behandlungen wie Paracetamol 
und NSAR ersetzt werden kann. Zusätzlich untersuchten wir die Auswirkungen von 
Hyaluronsäure (HA)- und HA-Kombinationen (Dexamethason, Acetaminophen oder 
Diclofenac) auf die Funktion und Viabilität von CSE exponierten Chondrozyten, um 
eine mögliche therapeutische Alternative für die klinische Anwendung bei Rauchern 
mit symptomatischer OA zu ermitteln. 
Humanes Knorpelgewebe, welches im Rahmen von Routineoperationen entnommen 
werden musste, wurde nach ethischer Genehmigung der Etikkomission des 
Universitätsklinikums Tübingen und mit schriftlicher Zustimmung des Patienten für 
die Isolation der Chondrozyten genutzt. Humane primäre Chondrozyten wurden 
physiologisch erreichbaren CSE Konzentrationen (0%, 0,1%, 0,5%, 1%, 5%, 10%) 
ausgesetzt, was Nikotinkonzentrationen von 3,6 ng / ml bis 72 ng / ml sowie 
Teerkonzentrationen von 40 ng / ml bis 800 ng / ml entspricht. Die Viabilität der 
Zellen wurde durch die Messung des Resazurinumsatzes sowie durch eine 
SRB-Färbung analysiert, die Matrixbildung wurde unter Verwendung von Alcianblau- 
und Safranin-O-Färbung gefärbt. Die Produktion freier Radikale wurde mit einem 
DCFH-DA-Assay bewertet. Die Genanalyse wurde mittels semi-quantitativer 
RT-PCR durchgeführt.  
Unsere vorliegende Studie zeigte, dass die mitochondriale Aktivität, der 
Gesamtproteingehalt und die Akkumulation von Matrix durch CSE in primären 
menschlichen Chondrozyten dosis- und zeitabhängig gehemmt wurden. Darüber 
hinaus führte erhöhter oxidativer Stress zu einem Zelltod von 10% CSE, was mit 
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ungefähr dem Rauchen einer Packung pro Tag verbunden ist. Als 
entzündungshemmende Behandlungsstrategie wurde die traditionelle 
pharmakologische Therapie mit Dexamethason (Dex) evaluiert. Klinische Dex-Dosen 
waren für die Zellen toxisch, und eine Langzeitinkubation mit niedrigeren Dex-Dosen 
(4–400 μg / ml) würde zu einem hypertrophen Chondrozyten-Phänotyp führen. Um 
Dexamethason zu ersetzen, wurde eine klinische Dosierung von Diclofenac (Dic) und 
Paracetamol (Ace) an Chondrozyten getestet. Interessanterweise verstärkten 
therapeutische Dosen von Dic (1 μg / ml) und Ace (10 μg / ml) die schädlichen 
Auswirkungen von CSE auf den Gesamtstoffwechsel von Chondrozyten nicht. 
Zusätzlich hatte eine klinische Dosis von HA (5 mg / ml) und HA in Kombination mit 
Dic, Ace oder Dosen von Dex eine schützende Wirkung auf die CSE-exponierten 
Chondrozyten, da sie die Bildung freier Radikale signifikant hemmten und die 
Lebensfähigkeit förderten und ECM-Akkumulation von Zellen. Unsere Studie zeigt, 
dass Zigarettenrauch durch Erhöhung des oxidativen Stresses den Zelltod induziert 
und die Knorpelbildung zerstört. Eine intraartikuläre (IA) Injektion von HA in 
Kombination mit therapeutischen Dosen von Analgetika / entzündungshemmenden 
Mitteln (Ace oder Dic) könnte die schädlichen Wirkungen von CSE auf primäre 
menschliche Chondrozyten umkehren und somit potenzielle therapeutische 
Alternativen bei der Behandlung von Rauchern für symptomatische Patienten 
eröffnen OA. 
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